Date: 2017-04-11
Type of information: Development agreement
Compound: Microbial Ecosystem Therapeutic products
Company: Takeda Pharmaceutical (Japan) NuBiyota (USA - NJ)
Therapeutic area: Gastrointestinal diseases
Type agreement: development
Action mechanism: NuBiyota’s Microbial Ecosystem Therapeutic is a clinic-ready microbial consortia which provides an entry point for clinical evaluation of microbiome based therapeutics which will enhance understanding of the role of microbiota in gastrointestinal disease.
Disease: gastrointestinal diseases
Details:
- • On April 11, 2017, Takeda Pharmaceutical announced a
strategic collaboration with NuBiyota or the development of Microbial Ecosystem Therapeutic products for gastroenterology indications with a high unmet medical need. Takeda and NuBiyota will collaborate to advance oral microbial consortia products developed by using NuBiyota’s microbiome platform for gastrointestinal indications.
Financial terms:
- NuBiyota will receive an upfront payment and is
eligible for success-based development, regulatory and commercial milestones and tiered royalties based on net sales. Further details of the agreement were not disclosed.
Latest news:
Is general: Yes
